Gastroenterology Research and Practice

Review Article

ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis

Table 1

Study characteristics included in meta-analysis.
Study IDStudyLT typeCountry and instituteStudy periodStudy typeArmsNo. of pts.Disease characteristicsFollow-upDZ protocolImmunosuppressantNos.
1Kim JM et al. (2018) [25]Adult LDLTSouth Korea, Samsung Medical Center2010 to 2015RetrospectiveABOi59HCCRituximab+TPEInduction: basiliximab+PGE1+gabexate mesilate+methylprednisolone.
Maintenance: corticosteroids+tacrolimus+MMF		9
      ABOc18131±19 months
2Yoon et al. (2018) [26]Adult LDLTSouth Korea, Asan Medical Center2008 to 2015RetrospectiveABOi165HCC48 monthsRituximab+TPE+LGITMaintenance: corticosteroids+tacrolimus+MMF9
      ABOc75348.7 months
3Song WG et al. (2016) [27]Adult LDLTSouth Korea, Asan Medical Center2008 to 2013RetrospectiveABOi235HBV, HCV, ALF, cirrhosis, and ACLFRituximab+TPE+LGIT±splenectomy±cyclophosphamideMaintenance: corticosteroids+tacrolimus+MMF+basiliximab8
      ABOc1301 
4Kim JM et. al (2016) [28]Adult LDLTSouth Korea, Samsung Medical Center2010 to 2013RetrospectiveABOi47HBV, HCV, ALF, HCC, alcoholic, cirrhosis, and ACLFRituximab+TPE±LGITMaintenance: corticosteroids+tacrolimus+MMF+basiliximab7
      ABOc94  
5Kim JD et al. (2016) [29]Adult LDLTSouth Korea, Catholic University of Daegu2011 to 2014RetrospectiveABOi25HBV, HCV, ALF, HCC, and ACLFRituximab+TPE+LGIT+MMFMaintenance: corticosteroids+tacrolimus+MMF7
      ABOc75  
6Kim SH et al. (2018) [22]Adult LDLTSouth Korea, National Cancer Center2014 and 2016RetrospectiveABOi43HBV, HCV, ALF, HCC, cirrhosis, and ACLFRituximab+IVIGInduction: basiliximab
Maintenance: corticosteroids+tacrolimus+MMF		7
      ABOc86  
7Lee CF et al. (2015) [30]Adult LDLTTaiwan, Chang-Gung Memorial Hospital2006 to 2013RetrospectiveABOi46HBV, HCV, ALF, HCC, alcoholic, cirrhosis, PBC, and ACLF>5 yearsRituximab±TPEMaintenance: corticosteroids+tacrolimus+MMF8
      ABOc340>5 years  
8Ikegami T et al. (2016) [31]Adult LDLTJapan, Kyushu University Hospital1997 to 2013RetrospectiveABOi19ALF, cholestatic disease, and cirrhosisRituximab+TPE+LGIT+splenectomy±IVIGMaintenance: corticosteroids+tacrolimus+MMF8
      ABOc389    
9Chae MS et al. (2018) [24]Adult LDLTSouth Korea, St. Mary’s Hospital2009 to 2016RetrospectiveABOi32HBV, HCV, ALF, alcoholic, autoimmune, and cryptogenicRituximab+TPE+LGITInduction: basiliximab
Maintenance: corticosteroids+tacrolimus+MMF		9
      ABOc32
ABOc—ABO compatible; ABOi—ABO incompatible; LGIT—local graft infusion therapy; MMF—mycophenolate mofetil; PGE1—prostaglandin E1; IVIG—intravenous immunoglobulin; TPE—total plasma exchange; NOS—Newcastle-Ottawa quality assessment scale; HBV—hepatitis B virus; HCV—hepatitis C virus; ACLF—acute-on-chronic liver failure; ALC—acute liver failure; PBC—primary biliary cirrhosis; DZ protocol—desensitization protocol.